Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 6/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | TDP2 | O95551 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 3/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6474904 | 1.00 | GRIA2 (0.51) | GRIA2KCNH2KIF11KDM1AGRIA4 | |
| SCHEMBL6474292 | 1.00 | GRIA2 (0.51) | GRIA2KCNH2KIF11KDM1AGRIA4 | |
| SCHEMBL6481818 | 0.93 | KDM1A (0.52) | GRIA2KCNH2KIF11KDM1AGRIA4 | |
| SCHEMBL6481826 | 0.86 | KIF11 (0.46) | GRIA2KCNH2KIF11KDM1AGRIA4 | |
| SCHEMBL6474298 | 0.86 | KIF11 (0.46) | GRIA2KCNH2KIF11KDM1AGRIA4 | |
| SCHEMBL6479531 | 0.86 | KIF11 (0.46) | GRIA2KCNH2KIF11KDM1AGRIA4 | |
| SCHEMBL6474044 | 0.83 | GRIA4 (0.48) | GRIA2KDM1AGRIA4 | |
| SCHEMBL6475291 | 0.83 | GRIA4 (0.62) | GRIA2GRIA4 | |
| SCHEMBL6482318 | 0.83 | GRIA4 (0.53) | GRIA2GRIA4 | |
| SCHEMBL6474261 | 0.82 | GRIA4 (0.47) | GRIA2GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911476-B2 | Sulfonamide derivatives | ELI LILLY AND COMPANY (US) | 2005-06-28 | — | — | US | claimed |
| US-20030225266-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-04 | — | — | US | claimed |
| EP-1265857-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| WO-2001068592-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-09-20 | — | — | WO | claimed |
| US-6911476-B2 | Sulfonamide derivatives | ELI LILLY AND COMPANY (US) | 2005-06-28 | — | — | US | disclosed |
| US-20030225266-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225266-A1 | Sulfonamide derivatives | GRIN2A, GRM2, GRIA2 | GRIA2 3/4885KCNH2 917/4885KIF11 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.